The impact of treatment with bile acid sequestrants on quality of life in patients with bile acid diarrhoea.

Abstract

BACKGROUND:

Bile acid diarrhoea (BAD) can be severely debilitating and negatively affect patients' quality of life (QoL). We carried out a multi-centre prospective study exploring QoL outcomes in patients with BAD after treatment with colesevelam.

METHODS:

Patients with or without a positive 23-seleno-25-homotaurocholic acid (SeHCAT) scan were recruited and categorised into four groups: SeHCAT negative control group (CG), idiopathic BAD, post-cholecystectomy (PC) and post-terminal ileal resection for Crohn's disease (CD). Patients with a positive SeHCAT were treated with colesevelam and dosing was titrated to symptomatic response. Patients were reviewed at 4- and 8-weekly intervals and QoL was evaluated by EQ-5D-3L, SF-36, IBDQ-32 at each visit (where relevant). Patients with a negative SeHCAT (CG cohort) completed one set of questionnaires before being discharged from the study.

RESULTS:

47 patients (BAD = 24, PC = 12, CD = 11) completed paired QoL questionnaires before and after treatment and 30 CG patients completed a baseline questionnaire. There was a significant improvement in IBDQ-32 mean scores before and after treatment in CD patients [134.6 (95%CI 112.5-156.6) and 158.4 (136.1-180.6), respectively (p = 0.007). Following treatment, BAD patients had significantly improved mean SF-36 scores in the "Role limitation due to physical health" dimension (p = 0.02) and in the overall mental component summary (p = 0.03). Prior to starting treatment, BAD patients had the lowest scores in the 'activity' dimension of the EQ-5D-3L (p = 0.04), which improved significantly after treatment (p = 0.002). Overall, the BAD and CD cohort showed improved mean scores with treatment in all components of the SF-36 and EQ-5D-3L, while the PC cohort showed a general decline in mean scores after treatment. 55% of patients clinically responded to treatment of which 41.7%, 58.3% and 81.8% responded from the BAD, PC and CD groups respectively. Correlations between those deemed as responders with improvements on the SF-36 and EQ-5D dimensions were not statistically significant.

CONCLUSION:

Our results demonstrate improved QoL in the BAD and CD cohort with treatment. Further larger studies are recommended specifically investigating the PC cohort and whether patients may improve with newer treatments such as FXR agonists. Trial registration Ethical approval REC Ref: 16/LO/1325.

• Authors: Aditi Kumar, Niall Galbraith, Hafid O Al-Hassi, Manushri Jain, Oliver Phipps, Jeffrey Butterworth, Helen Steed, John McLaughlin, Matthew J Brookes
• Journal: BMC gastroenterology (BMC Gastroenterol) Vol. 22 Issue 1 Pg. 325 (Jul 02 2022) ISSN: 1471-230X [Electronic] England
• PMID: 35778677 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Chemical References

• Bile Acids and Salts
• Colesevelam Hydrochloride

Topics

• Bile Acids and Salts (therapeutic use)
• Colesevelam Hydrochloride
• Crohn Disease (complications, drug therapy)
• Diarrhea (drug therapy, etiology)
• Humans
• Prospective Studies
• Psychometrics (methods)
• Quality of Life